Edwards Lifesciences Corporation $EW Shares Purchased by NEOS Investment Management LLC

NEOS Investment Management LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 12.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 94,229 shares of the medical research company’s stock after purchasing an additional 10,660 shares during the quarter. NEOS Investment Management LLC’s holdings in Edwards Lifesciences were worth $8,524,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in EW. BlackRock Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $11,168,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. Conway Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $954,000. Finally, TD Asset Management Inc increased its holdings in shares of Edwards Lifesciences by 6.4% in the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. UBS Group started coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, Mizuho upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Trading Up 0.2%

EW opened at $90.00 on Friday. The stock has a market capitalization of $51.82 billion, a PE ratio of 51.72, a P/E/G ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The business’s 50 day moving average price is $89.73 and its 200 day moving average price is $85.49.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,045 shares of company stock worth $457,749 over the last three months. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.